Using Acthar in Lemtrada Infusion Protocol

Background: Alemtuzumab is associated with infusion reactions in up to 92 % of individuals.  Prescribing information for Alemtuzumab recommends corticosteroids be given prior to at least the first three infusions to minimize these reactions.  There are persons who have been unable to tolerate corticosteroids and have used Repository Corticotropin Injection successfully.

Objectives: To describe the experience of 10 patients who received Repository Corticotropin Injection instead of Methylprednisolone.

Methods: Retrospective chart review of 10 patients experience

Results: Repository Corticotropin Injection can be successfully used to minimize infusion reactions to Alemtuzumab

Conclusions: Alemtuzumab is a highly efficacious therapy and its most common side effects are infusion reactions which are reduced by the use of corticosteroids. Persons who have not been able to tolerate Methylprednisolone have an option so they too can safely receive Alemtuzumab